Kairos Pharma to Present at H.C. Wainwright Global Investment Conference

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announced that CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel in New York.

The company's presentation at this prominent investment conference provides an opportunity to showcase its oncology research and development progress to potential investors and industry stakeholders. Kairos Pharma utilizes structural biology to address drug resistance and immune suppression in cancer, with its lead candidate ENV105 representing a novel approach to overcoming treatment limitations.

ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. The elevation of CD105 in response to standard therapy often results in resistance and disease relapse. By targeting CD105, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach addresses significant unmet medical needs in oncology, particularly for patients who develop resistance to existing treatments.

Currently, ENV105 is advancing through clinical trials, with a Phase 2 study underway for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer. The progress of these trials and additional company updates will likely be featured during the conference presentation. Investors and industry observers can access the latest news and updates relating to KAPA through the company's newsroom at https://ibn.fm/KAPA.

The H.C. Wainwright Global Investment Conference serves as an important platform for emerging biotechnology companies to connect with the investment community. Kairos Pharma's participation demonstrates the company's commitment to advancing its clinical programs and potentially expanding its investor base. The conference presentation may provide insights into the company's strategic direction, clinical milestones, and future development plans for its oncology pipeline.

For the investment community and healthcare sector, Kairos Pharma's approach to targeting cancer treatment resistance represents an important development in oncology therapeutics. Successful development of ENV105 could potentially benefit patients facing treatment-resistant cancers and contribute to the advancement of combination therapy approaches in oncology.